GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

Insilico Medicine has raised $110 million in Series E funding for its artificial intelligence-powered drug discovery ...

Indian Pharmaceuticals Market has delivered marginally lower revenue at 7.5% year on year in February 2025, compared to 8.7% ...

Paul Hudson, CEO at Sanofi, said: “Sanofi’s purpose in chasing the miracles of science reaches far beyond our labs […] This capital commitment signals Sanofi’s accelerated ambitions in the ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Wilmington, Delaware, Transparency Market Research Inc. –, March 07, 2025 (GLOBE NEWSWIRE) -- Rising awareness about women’s ...

Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor ...

Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.

By analyzing genes encoding B-cell and T-cell receptors, the model could screen for conditions like HIV, type 1 diabetes, and ...

Insilico Medicine('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced today that it has successfully secured a $110 million Series E ...

Rentosertib is designed to treat IPF by targeting Traf2- and NCK-interacting kinase (TNIK), a serine/threonine kinase whose activation plays a crucial role in cellular processes that include signal ...

Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...